In Q2 2026, Rock Springs Capital held 97 positions worth $2.0B. They initiated 12 new positions and exited 85. Their largest holding was RVMD ($207.0M). Portfolio value grew +18.5% versus the prior quarter.
Frequently asked questions
What stocks did Rock Springs Capital own in Q2 2026?
Rock Springs Capital held 97 biotech stocks in their 13F portfolio in Q2 2026. Their top positions include RVMD, TVTX, LLY, RYTM, MDGL. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Rock Springs Capital's portfolio worth in Q2 2026?
Rock Springs Capital's tracked biotech portfolio was worth $2.0B across 97 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Rock Springs Capital buy in Q2 2026?
Rock Springs Capital initiated 12 new positions in Q2 2026, including AVLN, COAG, PBLS, OMER, DFTX and 7 more. They also increased 39 existing positions.
What did Rock Springs Capital sell in Q2 2026?
Rock Springs Capital fully exited 85 positions in Q2 2026, including HUM, APLS, SRPT, BPMC, MREO and 80 more. They also trimmed 29 existing positions.
Is Rock Springs Capital a biotech fund?
Concentrated long/short healthcare fund focused on fundamental research. Rock Springs takes conviction-weighted positions based on deep pipeline analysis, therapeutic area expertise, and a willingness to be contrarian when the science supports it.
Want AI analysis, insider signals, and catalyst overlays for Rock Springs Capital?
View latest Rock Springs Capitalportfolio →